AMG-47a
AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC50=0.2 nM) . AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC50 of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].
Product Specifications
CAS Number
[882663-88-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
JAK; p38 MAPK; Src; VEGFR
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/AMG-47a.html
Purity
99.19
Solubility
DMSO : ≥ 34 mg/mL
Smiles
O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC=C(C)C(C3=CC4=CN=C(NCCN5CCOCC5)N=C4C=C3)=C2
Molecular Formula
C29H28F3N5O2
Molecular Weight
535.56
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items